Why DVAX Is Still a Buy
Here’s something you may not know about me… Years before I found my passion as an investment strategist, I was an undergrad biology major on the pre-med track. While life wound up having another plan (doesn’t it always?), I never forgot that foundation of medical knowledge I built in my college years. And it certainly comes in handy when I’m identifying investment opportunities in the biotech and pharmaceutical sectors. We have two such positions in the 10X Stocks portfolio, Dynavax Technologies (Nasdaq: DVAX) and Voyager Therapeutics (Nasdaq: VYGR). Both are showing early promise — with open gains of 35% and 76%, respectively.
Read More